首页> 美国卫生研究院文献>Medical Hypothesis Discovery and Innovation in Ophthalmology >Single-dose Intravitreal Bevacizumab after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: an Effective Adjunctive Treatment
【2h】

Single-dose Intravitreal Bevacizumab after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: an Effective Adjunctive Treatment

机译:全剂量视网膜光凝治疗增生性糖尿病性视网膜病变后单剂量玻璃体内贝伐单抗:一种有效的辅助治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Patients with proliferative diabetic retinopathy (PDR) who are refractory to complete panretinal photocoagulation (PRP) have a high risk of severe vision loss. The aim of this study was to evaluate the effectiveness of single-dose intravitreal bevacizumab (IVB) after complete PRP in patients with refractory PDR. Patients with retinal neovascularization (NV) secondary to diabetes mellitus and refractory to complete PRP were enrolled in this study. All patients received a single dose of 1.25 mg IVB at 3 months after completing the PRP. Patients underwent complete ophthalmic evaluation and fluorescein angiography (FA) at baseline and 1 month after injection. The main outcome measure was a reduction in the areas of leakage (mm2) on FA. All patients were evaluated at baseline and on every visit at 1 day, 1 week, and 1 month after the injection. A total of 21 consecutive patients (32 eyes) with PDR completed this study. Thirteen (61.9%) patients were female. The mean ± standard deviation (SD) age was 64.1 ± 5.6 years. Complete and partial response of angiographic leakage of NV was noted in 7 (21.9%) and 18 (56.2%) of 32 eyes after a single IVB injection, respectively. No satisfactory response of retinal NV was observed in 7 eyes (21.9%) at 1 month after the injection. No significant ocular or systemic adverse events were observed. A single-dose of IVB could be associated with a satisfactory response of retinal NV, secondary to PDR, in patients who are refractory to complete PRP.
机译:难以完成全视网膜光凝(PRP)的增生性糖尿病视网膜病变(PDR)患者有严重的视力丧失风险。这项研究的目的是评估完全PRP后难治性PDR患者的单剂量玻璃体内贝伐单抗(IVB)的有效性。本研究纳入了继发于糖尿病且难于完全完成PRP的视网膜新生血管形成(NV)患者。在完成PRP后的3个月,所有患者均接受1.25 mg IVB单剂量治疗。在基线和注射后1个月对患者进行全面的眼科评估和荧光血管造影(FA)。主要结果指标是减少FA渗漏面积(mm 2 )。在基线时以及注射后1天,1周和1个月的每次就诊中对所有患者进行评估。共有21例PDR连续患者(32眼)完成了本研究。十三名(61.9%)患者为女性。平均±标准差(SD)年龄为64.1±5.6岁。单次IVB注射后,分别在32只眼的7眼(21.9%)和18眼(56.2%)中发现了NV血管造影漏诊的完全和部分反应。注射后1个月,在7眼(21.9%)中未观察到满意的视网膜NV反应。没有观察到明显的眼部或全身不良事件。在难以完成PRP的患者中,单剂量IVB可能与PDR继发的视网膜NV的满意反应有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号